MPLT — MapLight Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for MapLight Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 27.7 | 79.8 | 109 | 305 |
| Prepaid Expenses | ||||
| Total Current Assets | 32 | 83.6 | 115 | 325 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 7.12 | 6.58 | 7.56 | 6.58 |
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 39.4 | 91.4 | 137 | 480 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 12.6 | 14.7 | 15.9 | 16.2 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 18.5 | 20.1 | 21.7 | 21.1 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 20.9 | 71.3 | 115 | 458 |
| Total Liabilities & Shareholders' Equity | 39.4 | 91.4 | 137 | 480 |
| Total Common Shares Outstanding |